person · Reporting owner

Cohen David E

Disclosed activity across 4 companies

Tapewire entity: 41841
SEC CIK: 0001347383

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Evommune, Inc.EVMN · Entity 5539	Director	June 02, 2026	June 04, 2026
Timber Pharmaceuticals, Inc.TMBR · Entity 110330	Director	April 15, 2023	April 18, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Evommune, Inc.

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,609	Ending reported balance After 2026-06-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-02 · Sale · Disposed 5,456 · Balance 18,209 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Row 2 · 2026-06-02 · Sale · Disposed 600 · Balance 17,609 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.82 · Expires 2036-06-01	Direct	15,673	Reported balance After 2026-06-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-02 · Grant · Acquired 15,673 · Balance 15,673 F4: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Timber Pharmaceuticals, Inc.

Report date April 15, 2023 · Filed April 18, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	6,100	Reported balance After 2023-04-15 transaction · row 1 1 source row Row 1 · 2023-04-15 · Grant · Acquired 4,100 · Balance 6,100 F1: On April 15, 2023, the Reporting Person was granted 4,100 restricted stock units, which will be settled in shares of common stock, par value $0.001. The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2032-04-14	Direct	4,100	Reported balance After 2023-04-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-04-15 · Grant · Acquired 4,100 · Balance 4,100 F2: 25% of the options vest on April 15, 2024, and the remaining shares will become exercisable in 36 equal monthly installments beginning on May 15, 2024, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On April 15, 2023, the Reporting Person was granted 4,100 restricted stock units, which will be settled in shares of common stock, par value $0.001. The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date.

F2: 25% of the options vest on April 15, 2024, and the remaining shares will become exercisable in 36 equal monthly installments beginning on May 15, 2024, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dermira, Inc.

Report date February 20, 2020 · Filed February 25, 2020

Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-02-20 transaction · row 1 1 source row Row 1 · 2020-02-20 · Disposition to issuer · Disposed 35,682 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Director Stock Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2021-10-03	Direct	Reported balance After 2020-02-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-20 · Disposition to issuer · Disposed 17,241 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2021-10-03	Direct	Reported balance After 2020-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-02-20 · Disposition to issuer · Disposed 8,620 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-05	Direct	Reported balance After 2020-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-20 · Disposition to issuer · Disposed 14,224 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10	Direct	Reported balance After 2020-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20	Direct	Reported balance After 2020-02-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12	Direct	Reported balance After 2020-02-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12	Direct	Reported balance After 2020-02-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03	Direct	Reported balance After 2020-02-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

Kadmon Holdings, Inc.

Report date November 09, 2021 · Filed November 09, 2021

Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2029-02-06	Direct	Reported balance After 2021-11-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-11-09 · Disposition to issuer · Disposed 64,935 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-05-15	Direct	Reported balance After 2021-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2030-05-13	Direct	Reported balance After 2021-11-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-09 · Disposition to issuer · Disposed 85,034 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2031-05-12	Direct	Reported balance After 2021-11-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-09 · Disposition to issuer · Disposed 96,975 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.

F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 02, 2026 Filed Jun 4, 2026 00:03 UTC	Evommune, Inc. EVMN · Entity 5539	GrantStock Option (Right to buy) · Derivative	15,673	$0.00 Strike: $19.82	$0.00	Disclosure SEC source: 0001347383-26-000003 · primarydocument.xml · derivative · entry 3 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,673 Underlying: Common Stock · 15,673 shares Expires 2036-06-01 F4 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:03 UTC	Evommune, Inc. EVMN · Entity 5539	SaleCommon Stock	600	$21.38	$12,828.00	Disclosure SEC source: 0001347383-26-000003 · primarydocument.xml · nonDerivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,609 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:03 UTC	Evommune, Inc. EVMN · Entity 5539	SaleCommon Stock	5,456	$20.21	$110,265.76	Disclosure SEC source: 0001347383-26-000003 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,209 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:17 UTC	Evommune, Inc. EVMN · Entity 5539	ConversionSeries Seed Preferred Stock · Derivative	51,588	Not disclosed	Not disclosed	Disclosure SEC source: 0001347383-25-000009 · form4-11122025_091132.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date. F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date. Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:17 UTC	Evommune, Inc. EVMN · Entity 5539	ConversionCommon Stock	6,056	Not disclosed	Not disclosed	Disclosure SEC source: 0001347383-25-000009 · form4-11122025_091132.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date. Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:15 UTC	Evommune, Inc. EVMN · Entity 5539	GrantStock Option (Right to Buy) · Derivative	37,960	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001347383-25-000007 · form4-11072025_041114.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,960 Underlying: Common Stock · 37,960 shares Expires 2035-11-04 F1 · derivative.exercise_date: One third (1/3) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
April 15, 2023 Filed Apr 18, 2023 15:32 UTC	Timber Pharmaceuticals, Inc. TMBR · Entity 110330	GrantStock Option (right to buy) · Derivative	4,100	$0.00 Strike: $1.66	$0.00	Disclosure SEC source: 0001437749-23-010513 · rdgdoc.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2032-04-14 F2 · derivative.exercise_date: 25% of the options vest on April 15, 2024, and the remaining shares will become exercisable in 36 equal monthly installments beginning on May 15, 2024, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date. Read SEC document
April 15, 2023 Filed Apr 18, 2023 15:32 UTC	Timber Pharmaceuticals, Inc. TMBR · Entity 110330	GrantCommon Stock, par value $0.001 per share	4,100	$0.00	$0.00	Disclosure SEC source: 0001437749-23-010513 · rdgdoc.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,100 F1 · shares: On April 15, 2023, the Reporting Person was granted 4,100 restricted stock units, which will be settled in shares of common stock, par value $0.001. The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date. Read SEC document
April 15, 2022 Filed Apr 19, 2022 16:59 UTC	Timber Pharmaceuticals, Inc. TMBR · Entity 110330	GrantStock Option (right to buy) · Derivative	100,000	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0001104659-22-047218 · tm2212708-5_4seq1.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.001 per share · 100,000 shares Expires 2032-04-14 F2 · derivative.exercise_date: 25% of the options vest on April 15, 2023, and the remaining shares will become exercisable in 24 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with the Issuer through each vesting date. Read SEC document
April 15, 2022 Filed Apr 19, 2022 16:59 UTC	Timber Pharmaceuticals, Inc. TMBR · Entity 110330	GrantCommon Stock, par value $0.001 per share	100,000	$0.00	$0.00	Disclosure SEC source: 0001104659-22-047218 · tm2212708-5_4seq1.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: On April 15, 2022, the Reporting Person was granted 100,000 restricted stock units, which will be settled in shares of common stock, par value $0.001, of Timber Pharmaceuticals, Inc. (the "Issuer"). The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2022, as long as the Reporting Person remains in continuous service with the Issuer through each vesting date. Read SEC document
November 09, 2021 Filed Nov 9, 2021 22:37 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	Disposition to issuerStock Option (right to buy) · Derivative	96,975	$5.92 Strike: $3.58	$574,092.00	Disclosure SEC source: 0001104659-21-136401 · tm2131118-4_4seq1.xml · derivative · entry 4 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 96,975 shares Expires 2031-05-12 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document
November 09, 2021 Filed Nov 9, 2021 22:37 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	Disposition to issuerStock Option (right to buy) · Derivative	85,034	$5.06 Strike: $4.44	$430,272.04	Disclosure SEC source: 0001104659-21-136401 · tm2131118-4_4seq1.xml · derivative · entry 3 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 85,034 shares Expires 2030-05-13 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document
November 09, 2021 Filed Nov 9, 2021 22:37 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	Disposition to issuerStock Option (right to buy) · Derivative	100,000	$7.21 Strike: $2.29	$721,000.00	Disclosure SEC source: 0001104659-21-136401 · tm2131118-4_4seq1.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document
November 09, 2021 Filed Nov 9, 2021 22:37 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	Disposition to issuerStock Option (right to buy) · Derivative	64,935	$7.23 Strike: $2.27	$469,480.05	Disclosure SEC source: 0001104659-21-136401 · tm2131118-4_4seq1.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 64,935 shares Expires 2029-02-06 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document
July 01, 2021 Filed Jul 6, 2021 20:06 UTC	Timber Pharmaceuticals, Inc. TMBR · Entity 110330	GrantStock Option (right to buy) · Derivative	71,893	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001104659-21-089394 · tm2121501-1_4.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,893 Underlying: Common Stock, par value $0.001 per share · 71,893 shares Expires 2031-07-01 F1 · date: The option grant was approved by the compensation committee of the board of directors of Timber Pharmaceuticals, Inc. (the "Company") on April 21, 2021, subject to stockholder approval of an amendment to the Company's 2020 Omnibus Equity Incentive Plan (the "Amendment"). The Company's stockholders approved the Amendment on July 1, 2021. F2 · derivative.exercise_date: The option grant will vest in 24 equal monthly installments beginning on August 1, 2021. Read SEC document
May 12, 2021 Filed May 13, 2021 20:10 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	GrantStock Option (right to buy) · Derivative	96,975	$0.00 Strike: $3.58	$0.00	Disclosure SEC source: 0001593968-21-001311 · primary_01.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,975 Underlying: Common stock · 96,975 shares Expires 2031-05-12 F1 · derivative.exercise_date: The stock option vests in full on the first anniversary of the grant date, or May 12, 2022 Read SEC document
May 13, 2020 Filed May 14, 2020 20:24 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	GrantStock Option (right to buy) · Derivative	85,034	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001593968-20-001174 · primary_01.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,034 Underlying: Common stock, $0.001 par value · 85,034 shares Expires 2030-05-13 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 13, 2021. F2 · balance_after: Only represents derivative securities of this class. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerRestricted Stock Unit · Derivative	3,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 10 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,000	Not disclosed Strike: $9.38	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 9 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,000	Not disclosed Strike: $9.95	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 8 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,000	Not disclosed Strike: $28.01	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 7 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	10,344	Not disclosed Strike: $28.82	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 6 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,344 shares Expires 2026-06-20 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	10,344	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 5 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,344 shares Expires 2025-06-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	14,224	Not disclosed Strike: $5.51	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 4 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,224 shares Expires 2024-06-05 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Stock Option (Right to buy) · Derivative	8,620	Not disclosed Strike: $0.99	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 3 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,620 shares Expires 2021-10-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Stock Option (Right to buy) · Derivative	17,241	Not disclosed Strike: $0.99	Not disclosed	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,241 shares Expires 2021-10-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerCommon Stock	35,682	$18.75	$669,037.50	Disclosure SEC source: 0001562180-20-001614 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document
June 12, 2019 Filed Jun 14, 2019 21:16 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003533 · primarydocument.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F2 · derivative.exercise_date: The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 12, 2019 Filed Jun 14, 2019 21:16 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003533 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 04, 2019 Filed Jun 7, 2019 00:15 UTC	Dermira, Inc. DERM · Entity 11896	GrantRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003403 · primarydocument.xml · derivative · entry 3 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 04, 2019 Filed Jun 7, 2019 00:15 UTC	Dermira, Inc. DERM · Entity 11896	GrantDirector Stock Option (right to buy) · Derivative	6,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0001562180-19-003403 · primarydocument.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document
May 15, 2019 Filed May 16, 2019 20:53 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	GrantStock Option (right to buy) · Derivative	100,000	$2.29 Strike: $2.29	$229,000.00	Disclosure SEC source: 0001593968-19-001126 · primary_01.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,935 Underlying: Common stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 15, 2020. F2 · balance_after: Only represents derivative securities of this class. Read SEC document
February 06, 2019 Filed Feb 7, 2019 21:24 UTC	Kadmon Holdings, Inc. KDMN · Entity 133686	GrantOption (right to buy) · Derivative	64,935	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001593968-19-000374 · primary_01.xml · derivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,935 Underlying: Common Stock, par value $0.001 · 64,935 shares Expires 2029-02-06 F1 · derivative.exercise_date: The option becomes vested and exercisable in three equal annual installments over 3 years from February 6, 2019, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document
June 13, 2018 Filed Jun 14, 2018 21:45 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-18-003003 · primarydocument.xml · derivative · entry 4 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F5 · derivative.exercise_date: The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 13, 2018 Filed Jun 14, 2018 21:45 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-18-003003 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents shares acquired upon vesting of RSU granted on June 13, 2017. Read SEC document
June 12, 2018 Filed Jun 14, 2018 21:45 UTC	Dermira, Inc. DERM · Entity 11896	GrantRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-18-003003 · primarydocument.xml · derivative · entry 3 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 12, 2018 Filed Jun 14, 2018 21:45 UTC	Dermira, Inc. DERM · Entity 11896	GrantDirector Stock Option (right to buy) · Derivative	6,000	$0.00 Strike: $9.95	$0.00	Disclosure SEC source: 0001562180-18-003003 · primarydocument.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document
March 01, 2018 Filed Mar 2, 2018 21:25 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$25.85	$15,510.00	Disclosure SEC source: 0001562180-18-001392 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,682 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 01, 2018 Filed Feb 2, 2018 21:46 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$28.87	$17,322.00	Disclosure SEC source: 0001562180-18-000590 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,282 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.85 to $28.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 02, 2018 Filed Jan 4, 2018 21:15 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$28.03	$16,818.00	Disclosure SEC source: 0001562180-18-000200 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,882 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
December 01, 2017 Filed Dec 5, 2017 21:00 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$25.49	$15,294.00	Disclosure SEC source: 0001562180-17-003741 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,482 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
November 01, 2017 Filed Nov 3, 2017 21:19 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$26.82	$16,092.00	Disclosure SEC source: 0001562180-17-003468 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,082 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
October 02, 2017 Filed Oct 3, 2017 20:02 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$26.99	$16,194.00	Disclosure SEC source: 0001562180-17-003164 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,682 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 01, 2017 Filed Sep 5, 2017 20:46 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$23.56	$14,136.00	Disclosure SEC source: 0001562180-17-002835 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,282 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 28, 2017 Filed Aug 29, 2017 23:12 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	600	$23.81	$14,286.00	Disclosure SEC source: 0001562180-17-002803 · primarydocument.xml · nonDerivative · entry 1 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,882 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 13, 2017 Filed Jun 15, 2017 21:11 UTC	Dermira, Inc. DERM · Entity 11896	GrantRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-17-002276 · primarydocument.xml · derivative · entry 3 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 13, 2017 Filed Jun 15, 2017 21:11 UTC	Dermira, Inc. DERM · Entity 11896	GrantDirector Stock Option (right to buy) · Derivative	6,000	$0.00 Strike: $28.01	$0.00	Disclosure SEC source: 0001562180-17-002276 · primarydocument.xml · derivative · entry 2 Cohen David E · CIK 0001347383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.